Cas:133891-59-5 (1-benzhydryl-3-methylazetidin-3-yl)methanamine manufacturer & supplier

Chemical Name:(1-benzhydryl-3-methylazetidin-3-yl)methanamine

CAS.NO:133891-59-5

Synonyms:3-aminomethyl-1-diphenylmethyl-3-methylazetidine

Molecular Formula:C₁₈H₂₂N₂

Molecular Weight:266.38100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:29.26000

Exact Mass:266.17800

LogP:3.69480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-aminomethyl-1-diphenylmethyl-3-methylazetidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-aminomethyl-1-diphenylmethyl-3-methylazetidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-aminomethyl-1-diphenylmethyl-3-methylazetidine Use and application,3-aminomethyl-1-diphenylmethyl-3-methylazetidine technical grade,usp/ep/jp grade.

Related News: Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. (1-benzhydryl-3-methylazetidin-3-yl)methanamine manufacturer American Airlines and Delta Air Lines announced more flight cancellations to China on Saturday as coronavirus cases continued to rise. (1-benzhydryl-3-methylazetidin-3-yl)methanamine supplier In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. (1-benzhydryl-3-methylazetidin-3-yl)methanamine vendor American Airlines and Delta Air Lines announced more flight cancellations to China on Saturday as coronavirus cases continued to rise. (1-benzhydryl-3-methylazetidin-3-yl)methanamine factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.